This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: polypill

Towards personalised medicine: HEART UK 28th Annual Conference

September 2014 Br J Cardiol 2014;21:104

Towards personalised medicine: HEART UK 28th Annual Conference

BJCardio Staff and others

Abstract

FH: improving detection in primary care The launch of the NICE (National Institute of Health and Care Excellence) guidelines for familial hypercholesterolaemia (FH) heralded great optimism for improving detection rates in primary care.1 Even with new research showing that FH is more common than previously thought,2  still around 80% of patients are not recognised. Novel detection approaches are clearly needed. Professor Nadeem Qureshi (University of Nottingham) presented preliminary findings from six GP centres taking part in FAMCHOL (Feasibility of Improving Identification of Familial Hypercholesterolaemia in General Practice: Intervention

| Full text

December 2012 Br J Cardiol 2013;20:14–5 Online First

News from the American Heart Association Scientific Sessions 2012

BJCardio Staff

Abstract

FREEDOM: CABG beats PCI in diabetes patients with multi-vessel disease Coronary artery by-pass graft (CABG) surgery was associated with better outcomes than percutaneous coronary intervention (PCI) in patients with diabetes with multi-vessel coronary artery disease in the FREEDOM (Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multi-vessel Disease) trial. Senior FREEDOM investigator, Dr Valentin Fuster (Mount Sinai School of Medicine, New York, USA), said the results (table 1) would change practice. He estimated that patients in this study represent about a quarter of patients undergoing PCI. In

| Full text

August 2012 Br J Cardiol 2012;19:107–10

Impressive results for polypill in new UK study 

BJCardio Staff

Abstract

The study, published on July 18 in PLoS One, was conducted by Dr David Wald (Wolfson Institute of Preventive Medicine, London) and colleagues. The polypill used contained three antihypertensive medications – the calcium antagonist, amlodipine 2.5 mg; the angiotensin-receptor blocker, losartan 25 mg; and the diuretic, hydrochlorothiazide 12.5 mg – in addition to the cholesterol-lowering agent simvastatin 40 mg. In the study, 86 individuals were randomised to the polypill or placebo for 12 weeks. They then crossed over and took the other treatment. Mean systolic blood pressure was reduced by 17.9 mmHg, diastolic pressure was reduced by 9.8

| Full text

August 2011 Br J Cardiol 2011;18:158–9

Old problems, new solutions: the HEART UK annual conference

BJCardio Staff

Abstract

Heart hotspots campaign The North/South divide in coronary heart disease (CHD) mortality remains significant despite improvements in cardiovascular disease (CVD) care, according to the ‘Heart Hotspots’ campaign launched at this year’s conference. The North West region has the highest mortality (93.72 per 100,000) versus South Central, which showed the lowest mortality (65.59 people per 100,000), according to NHS Information Centre data highlighted by the campaign (figure 1).1 CHD mortality in Tameside and Glossop, near Manchester, is almost four times as high as for those living in Kensington and Chelsea, London (140.84 vs. 36.91 people

| Full text

May 2009 Br J Cardiol 2009;16:121-125

News from the 58th Annual Scientific Session of the American College of Cardiology

BJCardio editorial staff

Abstract

Polypill could cut cardiovascular risk by half The strategy of giving a ‘polypill’, consisting of three antihypertensive drugs, a statin, and aspirin, to vast amounts of people who have not yet developed heart disease, could cut cardiovascular risk by half, according to the first major clinical trial of such an approach. The Indian Polycap Study (TIPS), presented at the ACC meeting by Dr Salim Yusuf (McMaster University, Hamilton, Ontario, Canada), included 2,053 patients aged 45–80 years without cardiovascular disease but with one risk factor (type 2 diabetes, high blood pressure, smoker within the past five years, increased waist-to-

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now